Effects of calcineurin inhibitors on sodium excretion in recipients of allogeneic hematopoietic stem cell transplantation

International Journal of Hematology
M SaburiT Mori

Abstract

Calcineurin inhibitors (CIs) such as cyclosporine A (CSA) and tacrolimus often cause renal dysfunction, resulting in increased serum creatinine, hyperkalemia, and hyperuricemia. However, the effects of CIs on sodium excretion have not been fully elucidated. We retrospectively evaluated the effects of CI administration on sodium excretion in recipients of allogeneic hematopoietic stem cell transplantation (HSCT). Fifty consecutive recipients each of allogeneic HSCT receiving either CSA or tacrolimus (100 patients in total) with available data for weekly fractional excretion of sodium (FENa) for a 4-week period after transplantation were enrolled in this retrospective analysis. No significant differences in patient characteristics were observed between CSA and tacrolimus groups except for the type of donor. FENa was significantly higher at the 3rd (1.25 ± 0.80) and 4th weeks (1.53 ± 1.06) after transplantation as compared with that at the 1st week (0.93 ± 0.51; P < 0.01, P < 0.001, respectively) in the tacrolimus group, but not at any time point in the CSA group. In addition, FENa was significantly higher in the tacrolimus group than the CSA group at the 4th week (1.53 ± 1.06 vs. 1.13 ± 0.80; P < 0.05). These results suggest that...Continue Reading

References

Jun 1, 1990·The British Journal of Dermatology·J Mason
Jul 1, 1983·American Journal of Nephrology·J UribarriH J Carroll
Jan 24, 2002·Current Opinion in Critical Care·A J OlyaeiW M Bennett
Mar 13, 2002·Lancet·Raimund Margreiter, UNKNOWN European Tacrolimus vs Ciclosporin Microemulsion Renal Transplantation Study Group
Jan 23, 2004·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Robert HigginsHabib Kashi
Apr 2, 2011·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Soumita BagchiRajendra Prasad Mathur
Jun 10, 2011·American Journal of Physiology. Renal Physiology·Kristien J LedeganckBenedicte Y De Winter
Feb 27, 2014·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Goce SpasovskiUNKNOWN Hyponatraemia Guideline Development Group
Apr 13, 2015·International Journal of Hematology·Makoto Murata

❮ Previous
Next ❯

Citations

Oct 10, 2019·Expert Opinion on Drug Metabolism & Toxicology·Yuan Gao, Jingjing Ma
Dec 5, 2020·Experimental and Clinical Transplantation : Official Journal of the Middle East Society for Organ Transplantation·Iman KarimzadehMani Ramzi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.